Microarray data of transcriptome shifts in blood cell subsets during S1P receptor modulator therapy

Area of Science:

• Immunology
• Neuroscience
• Pharmacogenomics

Background:

• Fingolimod, a sphingosine-1-phosphate (S1P) receptor modulator, is used to treat relapsing multiple sclerosis by limiting immune cell movement.
• Understanding fingolimod's molecular effects on immune cells is crucial for optimizing treatment and developing new therapies.

Purpose of the Study:

• To investigate the differential gene expression induced by fingolimod in distinct immune cell populations from multiple sclerosis patients.
• To analyze transcriptome shifts in T-cells, B-cells, monocytes, and natural killer cells after fingolimod initiation.

Main Methods:

• Peripheral blood samples were collected from relapsing multiple sclerosis patients before, one day after, and three months after starting fingolimod therapy.
• Five immune cell subpopulations (CD4+ T-cells, CD8+ T-cells, CD19+ B-cells, CD14+ monocytes, CD56+ NK cells) were isolated.
• Human Transcriptome Arrays (HTA 2.0) were used to analyze gene and transcript isoform expression, including alternative splicing patterns.

Main Results:

• After three months of fingolimod treatment, CD4+ and CD8+ T-cells exhibited substantial transcriptome alterations.
• B-cell profiles showed minor changes, while monocytes and natural killer cells remained largely unaffected at the transcriptomic level.
• The study generated a large dataset providing deep insights into alternative splicing in immune cell subsets.

Conclusions:

• Fingolimod induces significant, cell-specific transcriptomic changes, primarily impacting T-cells in multiple sclerosis patients.
• The findings offer a valuable dataset for comparing gene expression signatures of novel S1P receptor modulators.
• This research supports the development of new S1P modulators for autoimmune and neurodegenerative diseases.